Prothena Corp PLC (PRTA)
14.43
+0.03
(+0.21%)
USD |
NASDAQ |
Nov 21, 16:00
14.75
+0.32
(+2.22%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 776.46M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -57.77% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 5.849 |
| Price to Book Value | 1.453 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 89.99% |
Profile
| Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). |
| URL | https://www.prothena.com |
| Investor Relations URL | https://ir.prothena.com/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Feb. 14, 2025 (est.) |
| Last Earnings Release | Nov. 12, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). |
| URL | https://www.prothena.com |
| Investor Relations URL | https://ir.prothena.com/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Feb. 14, 2025 (est.) |
| Last Earnings Release | Nov. 12, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |